Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Quality guidelines for oral drug candidates: dose, solubility and lipophilicity.

Bayliss MK, Butler J, Feldman PL, Green DV, Leeson PD, Palovich MR, Taylor AJ.

Drug Discov Today. 2016 Oct;21(10):1719-1727. doi: 10.1016/j.drudis.2016.07.007. Epub 2016 Jul 14. Review.

PMID:
27423371
2.

Comparison of the bronchodilating effects of inhaled β₂-agonists after methacholine challenge in a human lung reperfusion model.

Gnadt M, Trammer B, Kardziev B, Bayliss MK, Edwards CD, Schmidt M, Högger P.

Eur J Pharm Biopharm. 2012 Aug;81(3):617-26. doi: 10.1016/j.ejpb.2012.04.013. Epub 2012 Apr 26.

PMID:
22561952
3.

Methacholine delays pulmonary absorption of inhaled β(2)-agonists due to competition for organic cation/carnitine transporters.

Gnadt M, Trammer B, Freiwald M, Kardziev B, Bayliss MK, Edwards CD, Schmidt M, Friedel G, Högger P.

Pulm Pharmacol Ther. 2012 Feb;25(1):124-34. doi: 10.1016/j.pupt.2011.12.009. Epub 2012 Jan 5.

PMID:
22245488
6.

A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes.

Somers GI, Lindsay N, Lowdon BM, Jones AE, Freathy C, Ho S, Woodrooffe AJ, Bayliss MK, Manchee GR.

Drug Metab Dispos. 2007 Oct;35(10):1797-805. Epub 2007 Jul 12.

PMID:
17627976
7.

Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver.

Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, Houston JB, Lake BG, Lipscomb JC, Pelkonen OR, Tucker GT, Rostami-Hodjegan A.

Curr Drug Metab. 2007 Jan;8(1):33-45. Review.

PMID:
17266522
8.

Drug metabolism assays and their use in drug discovery.

Bayliss MK, Eddershaw PJ.

Ernst Schering Res Found Workshop. 2002;(37):69-79. Review. No abstract available.

PMID:
11975201
9.

Combining high-throughput pharmacokinetic screens at the hits-to-leads stage of drug discovery.

Spalding DJ, Harker AJ, Bayliss MK.

Drug Discov Today. 2000 Dec 1;5(12 Suppl 1):70-76.

PMID:
11564569
11.

ADME/PK as part of a rational approach to drug discovery.

Eddershaw PJ, Beresford AP, Bayliss MK.

Drug Discov Today. 2000 Sep;5(9):409-414.

PMID:
10931658
12.

A commentary on the use of hepatocytes in drug metabolism studies during drug discovery and development.

Cross DM, Bayliss MK.

Drug Metab Rev. 2000 May;32(2):219-40. Review.

PMID:
10774777
13.

Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans.

Carlile DJ, Hakooz N, Bayliss MK, Houston JB.

Br J Clin Pharmacol. 1999 Jun;47(6):625-35.

14.
15.

The characterisation of the major metabolite of salmeterol in the dog.

Bowers GD, Bayliss MK, Donnelly MC, Fellows I, Ismail IM, Mookherjee CR.

J Pharm Biomed Anal. 1998 Nov;18(3):461-70.

PMID:
10096840
16.

High-throughput pharmacokinetics: cassette dosing.

Bayliss MK, Frick LW.

Curr Opin Drug Discov Devel. 1999 Jan;2(1):20-5.

PMID:
19649913
17.

Pharmacokinetics in Early Drug Research.

Leahy DE, Duncan R, Ahr HJ, Bayliss MK, de Boer AB, Darvas F, Fentem JH, Fry JR, Hopkins R, Houston JB, Karlsson J, Kedderis GL, Pratten MK, Prieto P, Smith DA, Straughan DW.

Altern Lab Anim. 1997 Jan-Feb;25(1):17-31. No abstract available.

PMID:
26554347
18.

Hockey stick or boomerang.

Dickins M, Bayliss MK.

Hum Exp Toxicol. 1996 Dec;15(12):980-1. No abstract available.

PMID:
8981102
19.

The aliphatic oxidation of salmeterol to alpha-hydroxysalmeterol in human liver microsomes is catalyzed by CYP3A.

Manchee GR, Eddershaw PJ, Ranshaw LE, Herriott D, Park GR, Bayliss MK, Tarbit MH.

Drug Metab Dispos. 1996 May;24(5):555-9.

PMID:
8723736
20.

Isolation and culture of human hepatocytes.

Bayliss MK, Skett P.

Methods Mol Med. 1996;2:369-89. doi: 10.1385/0-89603-335-X:369.

PMID:
21359755
21.

The effects of hypoxia on drug-metabolizing enzymes.

Woodrooffe AJ, Bayliss MK, Park GR.

Drug Metab Rev. 1995;27(3):471-95. Review. No abstract available.

PMID:
8521751
22.

7-Ethoxycoumarin O-deethylase kinetics in isolated rat, dog and human hepatocyte suspensions.

Bayliss MK, Bell JA, Wilson K, Park GR.

Xenobiotica. 1994 Mar;24(3):231-41.

PMID:
8009886
23.

Evaluation of pyrazole and ethanol induced S9 fraction in bacterial mutagenicity testing.

Burke DA, Wedd DJ, Herriott D, Bayliss MK, Spalding DJ, Wilcox P.

Mutagenesis. 1994 Jan;9(1):23-9.

PMID:
8208127
24.

Applications of molecular biology and in vitro technology to drug metabolism studies: an industrial perspective.

Tarbit MH, Bayliss MK, Herriott D, Hood SR, Hutson JL, Park GR, Serabjit-Singh CJ.

Biochem Soc Trans. 1993 Nov;21(4):1018-23. Review. No abstract available.

PMID:
8131890
25.

Effect of renal failure on drug metabolism by the liver.

Elston AC, Bayliss MK, Park GR.

Br J Anaesth. 1993 Aug;71(2):282-90. Review. No abstract available.

26.

Prediction of intrinsic clearance of loxtidine from kinetic studies in rat, dog and human hepatocytes.

Bayliss MK, Bell JA, Jenner WN, Wilson K.

Biochem Soc Trans. 1990 Dec;18(6):1198-9. No abstract available.

PMID:
1982435

Supplemental Content

Loading ...
Support Center